KR20230035592A - 벤조이소옥사졸 유도체 - Google Patents

벤조이소옥사졸 유도체 Download PDF

Info

Publication number
KR20230035592A
KR20230035592A KR1020237003716A KR20237003716A KR20230035592A KR 20230035592 A KR20230035592 A KR 20230035592A KR 1020237003716 A KR1020237003716 A KR 1020237003716A KR 20237003716 A KR20237003716 A KR 20237003716A KR 20230035592 A KR20230035592 A KR 20230035592A
Authority
KR
South Korea
Prior art keywords
group
alkoxy
alkyl
cycloalkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237003716A
Other languages
English (en)
Korean (ko)
Inventor
도모유키 다나카
요시아키 이소베
히로유키 기타노
히로아키 다나카
슌 나라이
?? 나라이
Original Assignee
스미토모 파마 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미토모 파마 가부시키가이샤 filed Critical 스미토모 파마 가부시키가이샤
Publication of KR20230035592A publication Critical patent/KR20230035592A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237003716A 2020-07-07 2021-07-06 벤조이소옥사졸 유도체 Pending KR20230035592A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020117236 2020-07-07
JPJP-P-2020-117236 2020-07-07
PCT/JP2021/025403 WO2022009863A1 (ja) 2020-07-07 2021-07-06 ベンゾイソキサゾール誘導体

Publications (1)

Publication Number Publication Date
KR20230035592A true KR20230035592A (ko) 2023-03-14

Family

ID=79553142

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003716A Pending KR20230035592A (ko) 2020-07-07 2021-07-06 벤조이소옥사졸 유도체

Country Status (11)

Country Link
US (2) US12534442B2 (https=)
EP (1) EP4180090A4 (https=)
JP (1) JP7326624B2 (https=)
KR (1) KR20230035592A (https=)
CN (1) CN115836058A (https=)
AU (1) AU2021303974A1 (https=)
BR (1) BR112022024340A2 (https=)
CA (1) CA3183354A1 (https=)
MX (1) MX2023000437A (https=)
TW (1) TW202214580A (https=)
WO (1) WO2022009863A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7324953B2 (ja) * 2022-01-12 2023-08-10 住友ファーマ株式会社 ベンゾイソキサゾール誘導体を含有する医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5377057A (en) 1976-12-16 1978-07-08 Dainippon Pharmaceut Co Ltd 1,2-benxisoxazole derivatives
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH037226A (ja) * 1989-03-24 1991-01-14 Dainippon Pharmaceut Co Ltd 虚血性脳障害治療薬
TW253885B (https=) 1992-12-15 1995-08-11 Ishihara Sangyo Kaisha
ES2244103T3 (es) * 1997-12-26 2005-12-01 Dainippon Pharmaceutical Co., Ltd. Remedio para enfermedades neurodegenerativas.
WO2001019321A2 (en) 1999-09-15 2001-03-22 Elan Pharmaceuticals, Inc. Methods for treating neuropathic pain using hetreoarylmethanesulfonamides
HK1252796A1 (en) 2015-09-30 2019-06-06 National University Corporation Nagoya University Therapeutic agent and/or prophylactic agent for peripheral nerve disorder or spinal injury
CN106810507B (zh) 2017-01-23 2019-06-21 珠海市海瑞德生物科技有限公司 一种唑尼沙胺的绿色环保合成方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5377057A (en) 1976-12-16 1978-07-08 Dainippon Pharmaceut Co Ltd 1,2-benxisoxazole derivatives
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Drug Discovery Today 11(5/6) 245-253(2006)
Neuron 98(3) 466-481(2018)
Pharmacological Reviews 57(4) 397-409(2005)
Q. Ashton Acton, PhD.(Eds.), Ion Channels-Advances in Research and Application. 2013 Edition. ScholarlyEditionsTM, Atlanta, Georgia, pp. 1-106.
비뇨기과 정기 간행물 57, 125-128(2011)

Also Published As

Publication number Publication date
BR112022024340A2 (pt) 2023-01-17
WO2022009863A1 (ja) 2022-01-13
CN115836058A (zh) 2023-03-21
JPWO2022009863A1 (https=) 2022-01-13
US12534442B2 (en) 2026-01-27
AU2021303974A1 (en) 2023-02-02
US20220289694A1 (en) 2022-09-15
MX2023000437A (es) 2023-02-09
US11535599B2 (en) 2022-12-27
EP4180090A1 (en) 2023-05-17
TW202214580A (zh) 2022-04-16
EP4180090A4 (en) 2024-10-09
US20230202991A1 (en) 2023-06-29
JP7326624B2 (ja) 2023-08-15
CA3183354A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
JP7374955B2 (ja) 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法
JP6609060B2 (ja) 置換ピペリジン化合物およびその用途
JP6275690B2 (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
CN112225695A (zh) 一种氮氧化合物及其制备方法和用途
UA121379C2 (uk) Проліки піридонамідів, застосовувані як модулятори натрієвих каналів
JPWO2019065791A1 (ja) 複素環化合物
KR102243135B1 (ko) 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진-3(2h)-온 유도체
US20200331908A1 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
EP2827870B1 (en) Chemical compounds
KR20080059297A (ko) 전압-개폐 나트륨 채널의 조절제로서의 ４급알파-아미노카르복스아미드 유도체
KR20230035592A (ko) 벤조이소옥사졸 유도체
JP2023503320A (ja) 肝臓ｘ受容体アゴニストとしての１，２，４－オキサジアゾール誘導体
JP7324953B2 (ja) ベンゾイソキサゾール誘導体を含有する医薬組成物
WO2022129303A1 (en) Dihydroisoquinolinyl derivatives
JP2007516235A (ja) アミドメチル置換２−（４−スルホニルアミノ）−３−ヒドロキシ−３，４−ジヒドロ−２ｈ−クロメン−６−イル誘導体、該誘導体を製造するための方法及び中間生成物並びにこれらの化合物を含有する医薬品
TW200804327A (en) Preventives/remedies for urinary disturbance
HK1254800A1 (zh) 2，3，4，5-四氢吡啶-6-胺衍生物
JP7798891B2 (ja) Ｄ１陽性アロステリック調節因子としての置換テトラヒドロイソキノリン誘導体
EA049705B1 (ru) Производное бензизоксазола
US20240239766A1 (en) 3-amino piperidyl sodium channel inhibitors
HK40091200A (en) Benzisoxazole derivative
NO325630B1 (no) Dofetilidpolymorf, fremgangsmate for fremstilling derav samt anvendelse derav for fremstilling av medikamenter og medisinske preparater.
WO2009056811A2 (en) Medicaments
JP2005500374A (ja) ＮＭＤＡ−アンタゴニストとしての置換された５，６，６ａ，１１ｂ−テトラヒドロ−７−オキサ−５−アザ−ベンゾ［ｃ］フルオレン−６−カルボン酸誘導体
EP3759098A1 (en) Pyridine-sulfonamide compounds and their use against pain and related conditions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000